Proteomics Market 2030: Global Size & Growth Guide
By Akhil Nair
Proteomics entails the applications of technologies for identifying and quantifying the protein content of an organism, tissue, or cell. It supports the other ‘omics’ technologies like transcriptomics and genomics to explain the identity of proteins of an organism and cognize the functions and structure of a specific protein. It is a fast-evolving molecular biology field concerned with the high-throughput, systematic approach to protein expression analysis of an organism or a cell.
According to Inkwood Research, the global proteomics market is projected to grow at a CAGR of 14.24% during the forecast period, 2022-2030, given the surging health concerns across the globe. As a result, there is a growing prioritization of research and development in drug discovery and biotechnology. In addition, proteomics technologies like mass spectrometry and biomarker identification offer growth opportunities.
In this regard, market players like Biognosys AG, PerkinElmer Inc, Thermo Fisher Scientific Inc, Shimadzu, Danaher Corporation, Agilent Technologies Inc, etc. are focused on launching improved and new proteomics techniques. For instance, Biognosys announced the launch of its extended proteomics suite of platforms that offer diagnostics and pharmaceutical consumers with deep biological insights.
Proteomics Market Scope
The global proteomics market scope includes the growth analysis of application and components. The components segment is further segmented into services, instruments, and reagents.
Drug Discovery had the largest revenue share of 59.67% in 2021 in the application segment. One of the most positive developments in the human genes and proteins study is the identification of the potential new drugs for disease treatment. Although it relies on the genome and proteome information to identify the proteins associated with a disease, it can be further used as targets for new drugs by computer software. The general applications of proteomics in the drug industry include target identification and validation, mechanism validation of drug action, and identifying the toxicity and efficacy biomarkers from readily accessible biological fluids.
Regional Market Analysis
Our geographical study for the global proteomics market includes the assessment of Europe, North America, Asia-Pacific, and Rest of World. The majority of the regions’ growth is attributed to the rising government initiatives to promote research and development in bioinformatics, genomics, and proteomics. Besides, the growing partnerships and collaborations among market players are contributing to the growth prospects of respective regions.
North America harbored the highest market share of 37.65% in 2021
The rising adoption of proteomic components for developing personalized therapeutics and advanced technologies primarily drives the North America proteomics market growth. Additionally, there has been expansive R&D on next-gen therapeutics. The region benefits from numerous modified therapeutic proteins in clinical trials for the treatment of age-related diseases, infections, immune disorders, and cancer.
Asia-Pacific expected to record the highest CAGR of 15.95% by 2030
The increasing influence of key players, the advancing medical infrastructure, and the developing economies boost the Asia-Pacific proteomics market growth. The region’s booming economic prospects facilitate advancements in healthcare. Besides, the growing geriatric population is set to boost market demands, given their vulnerability to diseases. Since proteomics helps understand the disease, devise treatment protocols, and design better drugs due to the comprehensive molecular picture, the region is evaluated as a conducive market for proteomics.
Demand for Personalized Medicine: Relevant Trend
The immense pressure on the global healthcare sector to provide more effective, affordable, quick, and reliable solutions. Therefore, scientific studies at the molecular level are necessary, for which proteomics offers large-scale opportunities for research findings and outcomes that have the potential to assist in providing better solutions.
Personalized medicines are evaluated as an effective treatment against rare generic conditions, neurodegenerative diseases, and cancer. The advancements in proteomic research have led to the development of personalized medicine by facilitating the detection of proteomics-based molecular diagnostics, pharmacoproteomics & protein biochips, and protein biomarkers.
Particularly, in cancer, personalized medicine is prescribed in accordance with the genetic modification, along with providing information about the patient’s treatment plan and tumor filing. As a result, the high prevalence of genetic diseases like cancer and infectious diseases like tuberculosis are surging the demand for personalized medicine, thereby boosting proteomics demands globally.
Future Potential Areas
The increased adoption of nano-proteomics presents lucrative growth opportunities for the global proteomics market. This is because nanotechnology supplements the study of post-translational modifications (PTM), biological complexities, and a vast range of molecules associated with proteomics. Furthermore, given the proteomics’ technologies to identify markers for cancer diagnosis, identify therapeutic targets, and monitor disease progression, they have become prominent in oncology.
Which is the prominent country in the global proteomics market?
The United States is the prominent country in the global proteomics market.
Which is the fastest-growing component of proteomics?
Services are the fastest-growing component of proteomics.